GO
Loading...

GlaxoSmithKline PLC

More

  • Britain to offer all infants meningitis B vaccine Sunday, 29 Mar 2015 | 12:08 PM ET

    LONDON— Britain says it will become the first country to offer all babies a vaccine for potentially fatal meningitis B after it reached a price deal with GlaxoSmithKline PLC. The drug was owned by Novartis, which recently sold most of its vaccines business to GlaxoSmithKline. Health Secretary Jeremy Hunt said Sunday he was "very proud that we will be the first...

  • March 19- GlaxoSmithKline Plc's drug to treat chronic breathing problems is safe and effective enough to be approved in adults with asthma, but not adolescents, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. The FDA is not obliged to follow the advice of its advisory panels but typically does so. Glaxo licensed the product from...

  • The FDA is not required to follow the recommendations of its experts, though it often does. Breo Ellipta is already approved in the U.S. for a type of chronic lung disease, but Glaxo is hoping to expand the drug's use to the much larger patient population of roughly 37 million Americans with asthma. In 2010, FDA required manufacturers of LABA-steroid combination...

  • FDA panel to discuss Ebola vaccine development in May Wednesday, 18 Mar 2015 | 8:16 AM ET

    March 18- The U.S. Food and Drug Administration said an advisory panel will discuss the development of Ebola vaccines, days after an American health worker was flown back after being tested positive for Ebola in Sierra Leone. Ebola has so far claimed about 10,000 lives in Sierra Leone, Liberia and Guinea. Other companies that are testing potential treatments for...

  • MGM and Black Diamond are big market movers Tuesday, 17 Mar 2015 | 5:20 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:. MGM Resorts International, up $2.08 to $21.74. BBX Capital Corp., up $4.87 to $18.50.

  • LONDON, March 17- Other big drugmakers may be reshaping their businesses but Novo Nordisk's focus on diabetes will get even bigger in the coming decade, according to the man most likely to be the Danish company's next boss. Kaare Schultz, who was made deputy chief executive in January 2014 and is the frontrunner to eventually succeed 60- year-old Lars Sorensen,...

  • The review comes two days ahead of a meeting of FDA advisers to discuss the combination treatment, Breo Ellipta, and recommend whether or not it should be approved to treat asthma. The FDA staff said on Tuesday there were no asthma-related deaths in Breo Ellipta studies it reviewed and that data on asthma-related hospitalizations were not observed uniformly...

  • March 17- GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems in treating asthma, a preliminary review by U.S. Food and Drug Administration staff found. The review comes two days ahead of a meeting of FDA advisers to discuss the combination treatment, Breo Ellipta, and recommend whether or not it...

  • *Backers include British govt, GSK, J&J, Pfizer, Lilly, Biogen. Drug companies involved include GlaxoSmithKline, Johnson& Johnson, Eli Lilly, Pfizer and Biogen Idec. The initiative, announced by Britain's health minister Jeremy Hunt at a meeting in Geneva on Tuesday, follows a Group of Eight nations conference in London in December 2013 that set a goal of finding a...

  • TRENTON, N.J.— Major drugmakers, the British government and a top Alzheimer's research charity are pooling more than $100 million to create a global fund to accelerate efforts to find a treatment or even a cure for the mind-robbing disease within a decade. Jeremy Hunt, the UK health secretary, was to announce the new fund Tuesday in Geneva at the World Health...

  • LONDON, March 17- The world's first venture capital fund dedicated to finding new ways to prevent and treat dementia has raised $100 million with the backing of the British government and several of the world's leading drugmakers. Drug companies involved include GlaxoSmithKline, Johnson& Johnson, Eli Lilly, Pfizer and Biogen Idec. The initiative, announced by...

  • LONDON, March 16- Scientists are to test a new two-shot Ebola vaccine using an experimental shot from Britain's GlaxoSmithKline, which is already in clinical trials in Africa, and a new kind of booster from Emergent BioSolutions. The Maryland- based biotech company said on Monday its modified vaccinia Ankara Ebola Zaire vaccine would be used in an initial Phase...

  • NEW YORK, March 12- Johnson& Johnson sued rival drugmaker GlaxoSmithKline PLC on Thursday, alleging that Glaxo is trying to unlawfully grab market share with false advertising at the start of spring allergy season in the United States. Two Johnson& Johnson units, McNeil-PPC Inc and McNeil Consumer Healthcare, filed the lawsuit in U.S. District Court in Manhattan.

  • LONDON, March 12- Pfizer is seeking new vaccine opportunities across the age spectrum as it broadens its portfolio by delivering shots into the arms of adolescents and the elderly, as well as infants. For many years the vaccines industry has been dominated by five big companies, but that has shrunk to four with GlaxoSmithKline's purchase of Novartis' business.

  • GSK's big bet: Tapping our body's electronics Wednesday, 11 Mar 2015 | 5:33 PM ET
    Test tubes and DNA sequence

    GSK expects it can design technology small and smart enough to manipulate our bodies' electrical systems and create new treatments for diseases.

  • LONDON/ GENEVA, March 5- Final stage trials of an Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7, the World Health Organization said on Thursday. Signalling global health authorities' determination to see through trials despite a sharp drop in cases in the West Africa epidemic, the WHO said a second shot, developed by...

  • GENEVA/ LONDON, March 5- Final stage of testing of an experimental Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7, the World Health Organization said on Thursday. All three worst-hit countries- Guinea, Liberia and Sierra Leone- aim to conduct Phase III final-stage clinical trials of experimental vaccines.

  • LONDON, March 4- The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's MAGE-A3. The idea of combining...

  • Early movers: BRK.B, AAPL, LL, CAH, BSX & more Monday, 2 Mar 2015 | 7:50 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • LONDON, March 2- GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers. GSK is forming a consumer health joint venture with Novartis, while at the same time buying the Swiss company's vaccines business and divesting its cancer drugs portfolio to Novartis.